From the Medical Board of the National Psoriasis Foundation: Vaccination in adult patients on systemic therapy for psoriasis

Lara Wine-Lee, Sara C. Keller, Marissa B. Wilck, Stephen J. Gluckman, Abby S. Van Voorhees

Research output: Contribution to journalReview article

Abstract

Patients with moderate to severe psoriasis often require systemic immunomodulatory medications that place them at risk for infection. Vaccination is a proven strategy to reduce infections. However, vaccination rates among patients with inflammatory autoimmune conditions, including psoriasis, remain low. We review the literature regarding vaccine-preventable illness and vaccinations commonly used in the United States in patients older than 18 years on immunosuppressive therapies that are used in the treatment of psoriasis. The medical board of the National Psoriasis Foundation recommends that dermatologists counsel patients on updating vaccinations in accordance with recommendations of the Advisory Committee for Immunization Practices as any measures taken to prevent infection can increase the safety of immunomodulatory therapies.

Original languageEnglish (US)
Pages (from-to)1003-1013
Number of pages11
JournalJournal of the American Academy of Dermatology
Volume69
Issue number6
DOIs
StatePublished - Dec 1 2013
Externally publishedYes

Keywords

  • biologics
  • cyclosporine
  • immunosuppressive therapy
  • inactivated vaccine
  • live vaccine
  • methotrexate
  • vaccine administration
  • vaccine counseling

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'From the Medical Board of the National Psoriasis Foundation: Vaccination in adult patients on systemic therapy for psoriasis'. Together they form a unique fingerprint.

  • Cite this